Sanofi (SAN) Given a €70.00 Price Target by Cfra Analysts

Sanofi (EPA:SAN) has been assigned a €70.00 ($86.42) price objective by investment analysts at Cfra in a research report issued to clients and investors on Monday. The brokerage currently has a “neutral” rating on the stock. Cfra’s target price would suggest a potential upside of 8.23% from the company’s current price.

A number of other analysts also recently commented on SAN. Goldman Sachs Group set a €82.00 ($101.23) price objective on Sanofi and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. Sanford C. Bernstein set a €82.00 ($101.23) price objective on Sanofi and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. Deutsche Bank set a €93.00 ($114.81) price objective on Sanofi and gave the stock a “buy” rating in a research note on Thursday. Berenberg Bank set a €97.00 ($119.75) price objective on Sanofi and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. Finally, Credit Suisse Group set a €95.00 ($117.28) price objective on Sanofi and gave the stock a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of €83.76 ($103.41).

Shares of Sanofi (EPA SAN) opened at €64.68 ($79.85) on Monday. Sanofi has a 12 month low of €63.09 ($77.89) and a 12 month high of €92.97 ($114.78). The company has a market capitalization of $81,700.00 and a price-to-earnings ratio of 21.42.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/sanofi-san-given-a-70-00-price-target-by-cfra-analysts.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply